2015-04-14-Bain-Global_Healthcare_Private_Equity_Report_2015_40页_5mb

Global Healthcare Private Equity Report 2015 Summary

Core Content

The Global Healthcare Private Equity Report 2015 is a collaborative effort between the Healthcare Private Equity Association (HCPEA) and Bain & Company. It provides an in-depth analysis of the healthcare private equity (PE) market in 2014, focusing on geographic and sector trends, investment strategies, and exit activity.

Main Points

Market Overview

• Deal value reached a three-year high, but deal count decreased.
• Valuations remained high due to strong public equity markets and strategic buyers.
• Large-scale assets over $1 billion were still in short supply, though midsize deals increased.
• Exit conditions were strong, with healthcare IPOs accounting for almost 40% of all debuts in the US.

Geographic Trends

• North America saw the majority of healthcare PE investments, driven by new care and payment models.
• Europe experienced notable growth in deal value, with four of the top 10 deals.
• Asia-Pacific showed mixed activity, with China as a bright spot due to new regulations, while India saw tempered investment.

Sector Trends

• Medtech and related services led the market, especially in Europe and China.
• Provider and related services remained the most active sector globally.
• Biopharma saw a decline in both deal value and count, though CXO, OTC manufacturers, and generics were notable subsectors.
• HCIT (Healthcare Information Technology) was a key focus, especially in the US.

Key Investment Strategies

• Carve-outs became more prominent, especially from large corporations, offering PE firms opportunities to deploy their turnaround capabilities.
• Buy-and-build strategies remained popular, with firms expanding their platform assets.
• Down-market investments were pursued by larger funds due to the scarcity of mega-deals.
• Early-stage and venture assets saw increased interest, especially in the US.

Exit Activity

• Exit conditions were robust, with exit numbers matching 2013's record levels.
• IPOs were a major exit channel, particularly in the US.
• Some assets from the 2006-2007 boom year still faced exit challenges.

Challenges and Opportunities

• High valuations led to crowded auctions and reduced deal count.
• Cost containment and healthcare reform were central themes across all regions.
• Regulatory changes in China and Italy positively impacted investment activity.
• Emerging markets like Brazil and Mexico saw increased PE interest due to favorable conditions and new opportunities.

Institutional Investors and PE Firms

• Large funds like Carlyle, General Atlantic, CD&R, TPG, OMERS, and CPPIB remained active.
• Strategic buyers continued to acquire assets to grow their portfolios, while also divesting noncore assets.
• PE firms focused on value creation through add-ons, operational improvements, and portfolio restructuring.

Strategic and Operational Support

• Bain & Company supports PE firms across various stages, including deal generation, due diligence, post-acquisition strategy, value addition, and exit planning.
• They also assist institutional investors in developing best-in-class investment programs, covering asset allocation, manager selection, and risk management.

Conclusion

2014 was a challenging yet dynamic year for healthcare PE, marked by high valuations, limited large-scale assets, and a shift in investment focus towards midsize and early-stage opportunities. The report highlights the importance of strategic alignment, innovative deal structures, and regulatory awareness in navigating the evolving healthcare landscape. As the market continues to transform, PE firms must remain agile and proactive in identifying and capitalizing on new opportunities.

Key Figures

• Global healthcare PE investment in 2014: $29.6 billion
• North America healthcare PE investment in 2014: $15.6 billion
• Europe healthcare PE investment in 2014: $9.6 billion
• Asia-Pacific healthcare PE investment in 2014: $4.4 billion
• Number of healthcare deals in 2014: 188
• Number of healthcare deals over $1 billion in 2014: 5

Summary of Trends

• Medtech saw a significant increase in deal value due to corporate carve-outs.
• Provider and related services remained the most active segment globally.
• Emerging markets like Brazil and China showed promise, while India faced macroeconomic uncertainties.
• Exit opportunities were strong, especially in the US, with healthcare IPOs making up a large portion of the market.

Risks and Considerations

• Currency risk increased due to the weakening euro.
• Regulatory complexity and political instability in Europe, particularly in Southern and Central Europe, posed challenges.
• Uncertainty in Greece and other regions impacted investment confidence and exit strategies.

This report serves as a comprehensive guide for PE investors, highlighting both the opportunities and challenges in the healthcare sector in 2014 and beyond.